UNASSIGNED: Maternal hormones are essential for the normal fetal development during pregnancy. @entity1669 is a frequent pathology in our @entity1496 replete region. The aim of this study is to evaluate the occurrence of @entity1375 ( @entity1375 ) in cases with known @entity1669 , which were in a euthyroid state prior to pregnancy, and to assess the association between supplemental treatments administered and the outcome of the pregnancy. The study is a prospective interventional controlled study. The two cohorts comprise the interventional group, consisting of 109 pregnant @entity1 with known autoimmune asymptomatic @entity1374 , without any @entity1955 ( @entity2016 ) treatment and an aged-matched control group, with an unknown @entity1374 . After the pregnancy, a monthly evaluation of TSH, FT3, and FT4 was performed. Offspring evaluation was made at birth time. 88.8% of the @entity1 developed @entity1375 in the first four weeks of pregnancy. Average LT4 doses increased as the pregnancy progressed. The monthly adjustment was 12.5 or 25  g. All @entity1375 cases developed in the first trimester of pregnancy. There was no significant difference regarding the gestational week, weight, or length at birth between the interventional group and controls, when TSH values were in the optimal range, during the whole pregnancy. Premature birth was described in one case in the interventional group.

Individualized Follow-up of Pregnant @entity1 with Asymptomatic XXXX .

@entity1 :: ('9606', 'Species') :: ['women'] @entity1375 :: ('MESH:D007037', 'Disease') :: ['subclinical hypothyroidism', 'SCH'] @entity1496 :: ('MESH:D007455', 'Chemical') :: ['iodine'] @entity1669 :: ('MESH:D013967', 'Disease') :: ['autoimmune thyroid disease', 'Autoimmune thyroid disease'] @entity1955 :: ('MESH:D013974', 'Chemical') :: ['levothyroxine'] @entity2016 :: ('CHEBI:18332', 'Chemical') :: ['LT4'] @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid disease']
@entity1669 :: (MESH:D013967,Disease) :: ['Autoimmune Thyroid Disease']
